300354-95-4

Basic information

• Product Name: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-
• CAS NO: 300354-95-4
• Molecular Formula: C15H20O4S
• Molecular Weight: 296.387
• Mol File: 300354-95-4.mol

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(300354-95-4)
• EPA Substance Registry System: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(300354-95-4)

Safety Data

• Hazardous Substances Data: 300354-95-4(Hazardous Substances Data)

Upstream product

• 300355-18-4 (4-methanesulfonyl-phenyl)-acetic acid methyl ester 
• 300355-19-5 3-cyclopentyl-2-(4-methanesulfonyl-phenyl)propionic acid methyl ester 
• 27935-87-1 cyclopentylmethyl Iodide 
• 90536-66-6 4-(methylsulfonyl)phenylacetic acid 
• 300355-05-9 3-cyclopentyl-2-(4-methylsulfanyl-phenyl)propionic acid 

Downstream Products

• 588940-26-5 2-[3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionylamino]-thiazole-5-carboxylic acid ethyl ester 
• 1080059-71-7 3-cyclopentyl-N-methoxy-N-methyl-2-[4-(methylsulfonyl)phenyl]propanamide 
• 1348539-58-1 C₁₉H₂₃N₃O₃S 
• 1393926-49-2 C₁₈H₂₁N₃O₅S₂ 
• 588939-98-4 N-(5-bromo-thiazol-2-yl)-3-cyclopentyl-2(R)-(4-methanesulfonyl-phenyl)-propionamide 
• 588939-85-9 C₁₈H₂₁ClN₂O₃S₂ 
• 300353-00-8 2-[3-cyclopentyl-2-(4-methanesulfonylphenyl)propionylamino]thiazole-4-carboxylic acid ethyl ester 
• 1393926-50-5 C₁₉H₂₃N₃O₃S 
• 1080059-89-7 3-cyclopentyl-N-(5-isopropylisoxazol-4-yl)-2-[4-(methylsulfonyl)phenyl]propanamide 
• 705980-78-5 3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionyl chloride 
• 300352-96-9 Ro 28-0450 

Relevant articles and documents

Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2 R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N- thiazol-2-yl-propionamide (RO0281675)

Glucokinase (GK) is a glucose sensor that couples glucose metabolism to insulin release. The important role of GK in maintaining glucose homeostasis is illustrated in patients with GK mutations. In this publication, identification of the hit molecule 1 and its SAR development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described. Compound 21a (RO0281675) was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.

Heteroaromatic Glucokinase Activators

The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; p

HETEROAROMATIC GLUCOKINASE ACTIVATORS

The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; p

SUBSTITUTED (THIAZOL-2-YL) -AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES

Compounds of the formula (I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention and treatm

Fused heteroaromatic glucokinase activators

Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.

Heteroaromatic glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.